Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
174 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Dec 30, 2010 | clinicaltrials |
| NCT00193466 | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Dec 30, 2010 | clinicaltrials |
| NCT00556088 | LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors | completed | Phase 1 | 40 | SCRI Development Innovations, LLCOTHER | 1 | Dec 30, 2010 | clinicaltrials |
| NCT00193622 | Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 0 | Sep 17, 2010 | clinicaltrials |
| NCT00193115 | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer | completed | Phase 2 | 32 | SCRI Development Innovations, LLCOTHER | 0 | Aug 4, 2010 | clinicaltrials |
| NCT00193193 | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Aug 4, 2010 | clinicaltrials |
| NCT00877045 | Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting | completed | — | 200 | SCRI Development Innovations, LLCOTHER | 1 | Aug 4, 2010 | clinicaltrials |
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 0 | Jul 28, 2010 | clinicaltrials |
| NCT00193362 | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer | completed | Phase 3 | 200 | SCRI Development Innovations, LLCOTHER | 0 | Jul 28, 2010 | clinicaltrials |
| NCT00193388 | Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Jul 28, 2010 | clinicaltrials |
| NCT00193401 | Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jul 28, 2010 | clinicaltrials |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | Jun 29, 2010 | clinicaltrials |
| NCT00193245 | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer | completed | Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00193323 | Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients | completed | Phase 2 | 346 | SCRI Development Innovations, LLCOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00193349 | Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 0 | Jun 28, 2010 | clinicaltrials |
| NCT00294931 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00193284 | Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 1 | Jun 22, 2010 | clinicaltrials |
| NCT00308529 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 55 | SCRI Development Innovations, LLCOTHER | 1 | Jun 22, 2010 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00193570 | Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors | completed | Phase 1 | 20 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00315861 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | completed | Phase 1 | 15 | SCRI Development Innovations, LLCOTHER | 1 | Jan 23, 2009 | clinicaltrials |
| NCT00611793 | PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies | completed | Phase 1 | 50 | SCRI Development Innovations, LLCOTHER | 1 | Jan 23, 2009 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials